Digestive Diseases and Sciences

, Volume 57, Issue 4, pp 1092–1101 | Cite as

Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma

  • Hirokazu Miyatake
  • Yoshiyuki Kobayashi
  • Yoshiaki Iwasaki
  • Shin-ichiro Nakamura
  • Hideki Ohnishi
  • Kenji Kuwaki
  • Junichi Toshimori
  • Hiroaki Hagihara
  • Kazuhiro Nouso
  • Kazuhide Yamamoto
Original Article

Abstract

Background and Aims

Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in HCV-related HCC patients.

Methods

Three hundred ninety-five patients who underwent curative treatment for HCV-related HCC were enrolled. Of these, 124 had received IFN treatment before the development of HCC (17 achieved sustained virological response [SVR group] and 107 did not [non-SVR group]), whereas 271 patients had never received IFN treatment (IFN-untreated group). The first and second recurrence and survival rates in these patient groups were statistically analyzed.

Results

The first HCC recurrence rate was similar among patient groups. In contrast, the second HCC recurrence rate was significantly lower in the SVR group than in the non-SVR group (p = 0.003) and the IFN-untreated group (p = 0.006). In multivariate analysis, platelet count (p = 0.033) and number of tumors (p = 0.001) were associated with the first HCC recurrence, while SVR (p = 0.002) was the only factor associated with the second HCC recurrence. The survival rate was higher in the SVR group than in non-SVR and IFN-untreated groups, and SVR to previous IFN treatment was an independent factor associated with better survival (p < 0.001).

Conclusions

SVR to previous IFN treatment before the development of HCV-related HCC was associated with lower risk of the second recurrence of HCC and better survival.

Keywords

Hepatocellular carcinoma Hepatitis C virus Previous interferon therapy Recurrence Survival 

Notes

Acknowledgments

The authors thank Dr. Kenji Miyoshi and Dr. Shota Iwadou for contribution to this study.

References

  1. 1.
    Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis. 1995;15:64–69. doi: 10.1055/s-2007-1007263.PubMedCrossRefGoogle Scholar
  2. 2.
    Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology. 1995;22:1027–1033.PubMedCrossRefGoogle Scholar
  3. 3.
    Tanaka K, Hirohata T, Koga S, et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res. 1991;51:2842–2847.PubMedGoogle Scholar
  4. 4.
    Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675–680. doi: 10.1056/NEJM199109053251002.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–1801. doi: 10.1056/NEJM199306243282501.PubMedCrossRefGoogle Scholar
  6. 6.
    Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517–524.PubMedGoogle Scholar
  7. 7.
    International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet. 1998;351:1535–1539.CrossRefGoogle Scholar
  8. 8.
    Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med. 1998;129:94–99.PubMedGoogle Scholar
  9. 9.
    Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–1402. doi: 10.1002/hep.510270529.PubMedCrossRefGoogle Scholar
  10. 10.
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–1055.PubMedCrossRefGoogle Scholar
  11. 11.
    Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196–197. doi: 10.1016/S0140-6736(00)03595-9.PubMedCrossRefGoogle Scholar
  12. 12.
    Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 1999;30:653–659.PubMedCrossRefGoogle Scholar
  13. 13.
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174–181.PubMedGoogle Scholar
  14. 14.
    Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991;214:114–117.PubMedCrossRefGoogle Scholar
  15. 15.
    Ikeda K, Arase Y, Kobayashi M, et al. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a long-term cohort study of 892 patients with viral cirrhosis. J Gastroenterol. 2003;38:865–876. doi: 10.1007/s00535-003-1163-2.PubMedCrossRefGoogle Scholar
  16. 16.
    Lam VWT, Ng KKC, Chok KSH, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008;207:20–29. doi: 10.1016/j.jamcollsurg.2008.01.020.PubMedCrossRefGoogle Scholar
  17. 17.
    N’Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009;50:1475–1483. doi: 10.1002/hep.23181.PubMedCrossRefGoogle Scholar
  18. 18.
    Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994;106:1618–1624.PubMedGoogle Scholar
  19. 19.
    Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol. 1993;160:1023–1028.PubMedGoogle Scholar
  20. 20.
    Kubo S, Nishiguchi S, Shuto T, et al. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res. 1999;90:162–170.PubMedCrossRefGoogle Scholar
  21. 21.
    Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96:975–981. doi: 10.1002/bjs.6731.PubMedCrossRefGoogle Scholar
  22. 22.
    Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–232. doi: 10.1053/jhep.2000.9409.PubMedCrossRefGoogle Scholar
  23. 23.
    Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418–422. doi: 10.1046/j.0007-1323.2001.02054.x.PubMedCrossRefGoogle Scholar
  24. 24.
    Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001;134:963–967.PubMedGoogle Scholar
  25. 25.
    Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–1554. doi: 10.1002/hep.21415.PubMedCrossRefGoogle Scholar
  26. 26.
    Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol. 2010;52:889–894. doi: 10.1016/j.jhep.2009.12.041.PubMedCrossRefGoogle Scholar
  27. 27.
    Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138:299–306.PubMedGoogle Scholar
  28. 28.
    Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–858. doi: 10.1111/j.1365-2036.2010.04414.x.PubMedCrossRefGoogle Scholar
  29. 29.
    Komorizono Y, Sako K, Yamasaki N, et al. Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy. Anticancer Res. 2002;22:3573–3578.PubMedGoogle Scholar
  30. 30.
    Kubo S, Nishiguchi S, Hirohashi K, et al. Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma. Jpn J Cancer Res. 2001;92:59–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Uenishi T, Kubo S, Hirohashi K, et al. Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2002;24:404–412.PubMedCrossRefGoogle Scholar
  32. 32.
    Uenishi T, Nishiguchi S, Tamori A, et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006;36:195–200. doi: 10.1016/j.hepres.2006.07.011.PubMedCrossRefGoogle Scholar
  33. 33.
    Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest. 1990;86:1764–1767. doi: 10.1172/JCI114903.PubMedCrossRefGoogle Scholar
  34. 34.
    Farmer DG, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for hepatocellular carcinoma. Ann Surg. 1994;219:236–247.PubMedCrossRefGoogle Scholar
  35. 35.
    Lee MJ, Mueller PR, Dawson SL, et al. Percutaneous ethanol injection for the treatment of hepatic tumors: indications, mechanism of action, technique, and efficacy. AJR Am J Roentgenol. 1995;164:215–220.PubMedGoogle Scholar
  36. 36.
    Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655–661.PubMedGoogle Scholar
  37. 37.
    Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994;74:817–825.PubMedCrossRefGoogle Scholar
  38. 38.
    Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224–1229. doi: 10.1053/jhep.2000.20456.PubMedCrossRefGoogle Scholar
  39. 39.
    Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–491.PubMedCrossRefGoogle Scholar
  40. 40.
    Moriyama M, Matsumura H, Aoki H, et al. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. Intervirology. 2003;46:296–307. doi: 10.1159/000073209.PubMedCrossRefGoogle Scholar
  41. 41.
    Taniguchi H, Iwasaki Y, Fujiwara A, et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol. 2006;21:281–287. doi: 10.1111/j.1440-1746.2006.04201.x.PubMedCrossRefGoogle Scholar
  42. 42.
    Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065–1067. doi: 10.1038/2053.PubMedCrossRefGoogle Scholar
  43. 43.
    Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. Liver Int. 2004;24:603–610. doi: 10.1111/j.1478-3231.2004.0956.x.PubMedCrossRefGoogle Scholar
  44. 44.
    Imai Y, Tamura S, Tanaka H, et al. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat. 2010;17:185–191. doi: 10.1111/j.1365-2893.2009.01163.x.PubMedCrossRefGoogle Scholar
  45. 45.
    Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies—a multicenter prospective trial. J Hepatol. 2011;54:219–226. doi: 10.1016/j.jhep.2010.07.011.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Hirokazu Miyatake
    • 1
  • Yoshiyuki Kobayashi
    • 1
  • Yoshiaki Iwasaki
    • 1
  • Shin-ichiro Nakamura
    • 1
  • Hideki Ohnishi
    • 1
  • Kenji Kuwaki
    • 1
  • Junichi Toshimori
    • 1
  • Hiroaki Hagihara
    • 1
  • Kazuhiro Nouso
    • 1
  • Kazuhide Yamamoto
    • 1
  1. 1.Department of Gastroenterology and HepatologyOkayama University Graduate School of Medicine, Dentistry, and Pharmaceutical SciencesOkayamaJapan

Personalised recommendations